目前对恶性脑肿瘤的治疗效果有限，需要新的治疗策略。本研究旨在评估反义寡核苷酸（ASO）作为高级别胶质瘤辅助治疗的潜力，重点关注其中枢神经系统渗透和临床转化前景。对现有文献进行了全面回顾，以评估 ASO 在神经胶质瘤中的影响。肿瘤学。对 ASO 疗法的疗效、中枢神经系统渗透性和安全性的研究进行了分析，以评估其作为高级别神经胶质瘤治疗干预的潜力。ASO 为增强恶性神经胶质瘤的靶向基因治疗提供了一条有前途的途径。它们有效的中枢神经系统渗透、体内持久性和高效的转导提供了优于传统治疗的优势。初步的体内和体外研究表明，ASO 作为高级神经胶质瘤的一种可行的辅助治疗，值得在临床试验中进一步探索。ASO 作为高级神经胶质瘤的辅助治疗具有重大前景，与现有治疗方法相比，ASO 具有更好的中枢神经系统渗透性和持久性。虽然初步研究令人鼓舞，但还需要进行更多研究来确定 ASO 疗法在临床环境中的安全性和有效性。需要进一步的研究和临床试验来验证 ASO 作为神经肿瘤学的变革性方法。

The limited efficacy of current treatments for malignant brain tumors necessitates novel therapeutic strategies. This study aimed to assess the potential of antisense oligonucleotides (ASOs) as adjuvant therapy for high-grade gliomas, focusing on their CNS penetration and clinical translation prospects.A comprehensive review of the existing literature was conducted to evaluate the implications of ASOs in neuro-oncology. Studies that investigated ASO therapy's efficacy, CNS penetration, and safety profile were analyzed to assess its potential as a therapeutic intervention for high-grade gliomas.ASOs present a promising avenue for enhancing targeted gene therapies in malignant gliomas. Their potent CNS penetration, in vivo durability, and efficient transduction offer advantages over conventional treatments. Preliminary in vivo and in vitro studies suggest ASOs as a viable adjuvant therapy for high-grade gliomas, warranting further exploration in clinical trials.ASOs hold significant promise as adjuvant therapy for high-grade gliomas, offering improved CNS penetration and durability compared with existing treatments. While preliminary studies are encouraging, additional research is needed to establish the safety and efficacy of ASO therapy in clinical settings. Further investigation and clinical trials are warranted to validate ASOs as a transformative approach in neuro-oncology.